BOT
$92MCF+
Botanix Pharmaceuticals
Biotech · Dermatology
Dermatology-focused with FDA-approved SOFDRA for hyperhidrosis
Cash data from Dec 2025 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$47.9M
Dec 2025 4C
Runway
CF+Cash Flow Positive
Based on Dec 2025 4C
Market Cap
$92M
Burn Rate
—
Dec 2025 4C
Shares Outstanding
2.7B
Pipeline Assets
2
Latest Insight(1)
16 Apr 2026Insider TradeChange of Director's Interest Notice x5
3 transactions·+$250k net buyIppolito: bought $100kBosch: bought $100kSharp: bought $50k
3M Price
BOT.ASX$0.034-73.8% 3M
Low $0.034High $0.130
Pipeline Assets (2)
BX002Acne vulgaris
Phase 2SOFDRA (sofpironium)Primary axillary hyperhidrosis
ApprovedDiscovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Approved
BX002
Acne vulgaris
Capital Raises & Buybacks
2 raises
Current shares outstanding: 2.7B
SPP
2026-03-11spp
0
2026-03-11spp
$5.0M
Director Transactions
3 transactionsLast 90dNet Buy
Buys3+3 vs prior
Sells0
Buy Value$250k
warning3 directors bought within 30 days (04-10 – 04-10) — $250k total
warningVincent Peter Ippolito bought 20d before "SOFDRA quarterly revenue update" ($100,000)
warningDr Henry William Bosch bought 20d before "SOFDRA quarterly revenue update" ($100,000)
Substantial Holders (5%+ threshold)
2 noticesCEASEDInsignia Financial Ltd
CEASEDInsignia Financial Ltd
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Short Interest
ASIC ↗as of 2026-03-27 · 4-day lag
Short position
0.30%
arrow_drop_down-2.38% over 30 reports
Shares short
6.6M
Aggregated short position data published by ASIC under the Corporations Act. T+4 reporting lag applies. Short interest ≥5% is noteworthy; ≥10% is elevated. Source: ASIC Short Selling Data
R&D Tax Incentive
$18.0M pending43.5% ATO refund
FY2026estimated
Tracker estimate only — calculated as 43.5% of annualised R&D spend from last 4 quarters of 4C filings. Not AusIndustry-registered. Actual refund will depend on FY2026 eligible spend. Refund expected Oct–Dec 2026.
$17.97M
expected
How the R&D Tax Incentive works
Australian biotechs with < $20M aggregated turnover can claim a 43.5% refundable tax offseton eligible R&D expenditure each financial year (Jul–Jun). This is paid as a cash refund by the ATO — not a tax deduction — making it non-dilutive capital that directly extends cash runway.
Companies register eligible R&D activities with AusIndustry during the year, then lodge their tax return after 30 June. Refunds typically arrive October–Decemberof the same calendar year. For a company spending $5M/year on R&D, this is a ~$2.2M annual cash inflow.
Disclaimer: Amounts shown as estimated or registeredare forward-looking estimates based on disclosed R&D expenditure and the 43.5% offset rate. Actual refunds may differ due to ATO assessments, eligibility rulings, or changes in R&D spend. This is not financial advice. Manually curated from 4C filings and company disclosures — verify independently.
Competitive Landscape
5 approved drugs51 competitor trialsPhase 2+ · Non-ASX
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
expand_moreClinical Publications
Peer-reviewed papers & conference abstracts via PubMed
6 papers
Clinical Publications
Peer-reviewed papers & conference abstracts via PubMed
Clin Drug Investig2026-04· sofpironium
Skin Therapy Lett2026-03· sofpironium
Am Fam Physician2025-12· sofpironium
J Dermatolog Treat2025-12· sofpironium
Catalysts (23)· 2 upcoming · 21 past
SOFDRA quarterly revenue update
UpcomingConfirmedarrow_upwardHigh30 Apr 2026
BX002 Phase 2 acne topline data
UpcomingExpectedarrow_upwardHigh30 June 2026
expand_more21 past catalysts
AAD 2026 presentation
CompletedConfirmedremoveMed28 Mar 2026
Presented at AAD 2026 annual meeting (Mar 26-29, San Francisco)
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
1/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
High96/100
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Hit 1 of 1 guided dates· rolling 2yr(limited sample)· of 23 tracked
Filing discipline not scored — this company reports under US regime (Form 10-K / 10-Q). ASX Listing Rule 4.7C deadlines don't apply.
What drove these scores · rolling 2yr
arrow_drop_up
Turning CF positive — Latest quarter operating cash flow positive — transition in progress
arrow_drop_up
Burn reductions achieved — 1 quarter with >30% spend reduction
arrow_drop_up
Cash position improving — Cash balance grew over last 3 quarters
arrow_drop_up
R&D-focused spend — 82% of opex directed to R&D
·
Mixed cash flow — Burn volatility calculated from 4 burning quarters only
·
Phase 3+ thresholds — Burn rate variability thresholds adjusted for late-stage development
Completed catalysts
✓AAD 2026 presentation· presentation — scheduled date— Presented at AAD 2026 annual meeting (Mar 26-29, San Francisco)
On time
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
⚠ TIMELINE CHANGESCT.GOV · AUTO-DETECTED
These changes were automatically detected by comparing ClinicalTrials.gov records over time. A slipped date means the trial's expected completion moved later; pulled forward means it moved earlier.
★ RESULTS